Code Clarity

Grab a biccie & cuppa as we gossip about the GSK campaign complaints (Cases: 0269, 0568 & 0874) .... genuine gasps from Rina when Jean explains how the "courtesy copy" bit them in the bum

It's faster, and done right, good for everyone at the table. So why does the PMCPA's Abridged Procedure remain the road less travelled? Rina & Jean investigate the case for using it more: the benefits for companies facing complaints, for complainants seeking resolution, and for the PMCPA itself. If it works this well, what's holding the PMCPA back?

The PMCPA has released its 2025 Annual Report - but does the data point to a genuinely transformational year, or business as usual? In this episode, Rina & Jean dig into the numbers to ask the question everyone in pharma is thinking: are companies actually getting more compliant, or are complaints simply getting worse?

Whether you are a new or seasoned signatory, the question of signatory standards is worth considering. Two experienced signatories (Rina & Jean) chat about 3 of the most important standards (the full 10 will be discussed in detail at our subscribers webinar on 17 Sept 26 - get in touch at [email protected] if you are not a subscriber).

Why does this matter to you? Because for the first time 'it happened ages ago' is now a legitimate defence (within limits). PMCPA Q&A on policy here.